Opus Genetics doses first patient in pivotal LYNX-3 phase 3 trial evaluating phentolamine ophthalmic solution 0.75% in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions
Opus Genetics, Inc., a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies…